Advicenne SA logo

ADVIC - Advicenne SA News Story

€7.08 0.1  1.1%

Last Trade - 3:46pm

Sector
Healthcare
Size
Small Cap
Market Cap £52.9m
Enterprise Value £39.0m
Revenue £1.49m
Position in Universe 558th / 852

BRIEF-Advicenne Says EMA Granted ADV7103 Orphan Drug Designation

Wed 18th December, 2019 5:00pm
Dec 18 (Reuters) - Advicenne SA  ADVIC.PA :
    * ANNOUNCED THAT ITS LEAD DRUG CANDIDATE, ADV7103, HAS BEEN
GRANTED ORPHAN DRUG DESIGNATION BY EUROPEAN MEDICINES AGENCY
(EMA) FOR TREATMENT OF CYSTINURIA IN EUROPE.
    * ADV7103 AND IS CURRENTLY IN PHASE III TRIALS FOR THIS
INDICATION
IN UNITED STATES AND CANADA

Source text for Eikon:  ID:nBw1PWhnXa 
Further company coverage:  ADVIC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.